September 18, 2017

IBALIZUMAB Long-Term Safety and  Efficacy Data to be Presented at IDWEEK 2017 in SAN DIEGO

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that the abstract entitled “48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1” will be featured in an oral presentation at the IDWeek Conference to be held in San Diego, CA, from October 4 to 8, 2017. Dr. Brinda Emu, Assistant Professor of Medicine, Infectious Diseases, Yale School of Medicine, New Haven, CT will be presenting detailed data related to the long-term efficacy and safety of ibalizumab, an investigational drug. The presentation will be held during the afternoon session on October 6, 2017, entitled Modern ART.